Pramiracetam

Structural formula
General
Non-proprietary name	Pramiracetam
other names	N - [2- (Diisopropylamino) ethyl] -2-oxopyrrolidine-1-acetamide ( IUPAC )
Molecular formula	C 14 H 27 N 3 O 2 (pramiracetam) ; C 14 H 27 N 3 O 2 · H 2 SO 4 (pramiracetam sulfate) ;
External identifiers / databases
EC number	806-175-7
ECHA InfoCard	100.233.221
PubChem	51712
Wikidata	Q415746
Drug information
ATC code	N06 BX16
Drug class	Nootropics
properties
Molar mass	269.38 g · mol -1 (pramiracetam) ; 367.46 g · mol -1 (Pramiracetam Sulfate) ;
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances Caution
H and P phrases	H: 302
	P: ?
Toxicological data	4355 mg kg −1 ( LD 50 , mouse , oral , pramiracetam sulfate)
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Pramiracetam is a drug from the group of nootropics . After traumatic brain injuries, Pramiracetam is said to improve the limited mental abilities. Its mechanism of action is largely unknown. The therapeutic use of pramiracetam is considered controversial.

Manufacturing

The synthesis takes place starting from 2-pyrrolidone in the first step by reaction with ethyl bromoacetate. In the second step, the target compound is obtained by reacting with N , N- diisopropylethylenediamine.

Individual evidence

↑ Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of [No public or meaningful name is available] in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed on July 11, 2020, is reproduced from a self-classification by the distributor .
↑ Entry on pramiracetam in the ChemIDplus database of the United States National Library of Medicine (NLM), accessed on July 11, 2020.
↑ AG Malykh, MR Sadaie: Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders . In: Drugs . tape 70 , no. 3 , February 2010, p. 287-312 , doi : 10.2165 / 11319230-000000000-00000 , PMID 20166767 .
↑ Donald E. Butler, Ivan C. Nordin, Yvon J. L'Italien, Lynette Zweisler, Paul H. Poschel, John G. Marriott: Amnesia-reversal activity of a series of N - [(disubstituted-amino) alkyl] - 2-oxo-1-pyrrolidine acetamides, including pramiracetam . In: Journal of Medicinal Chemistry . tape 27 , no. 5 , 1984, pp. 684-691 , doi : 10.1021 / jm00371a023 .
^ Axel Kleemann , Jürgen Engel, Bernd Kutscher, Dietmar Reichert: Pharmaceutical Substances. 4th edition. 2000, 2 volumes published by Thieme-Verlag Stuttgart, ISBN 978-1-58890-031-9 ; online since 2003 with biannual additions and updates.

[1] Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of [No public or meaningful name is available] in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed on July 11, 2020, is reproduced from a self-classification by the distributor .

[ChemIDplus-2] Entry on pramiracetam in the ChemIDplus database of the United States National Library of Medicine (NLM), accessed on July 11, 2020.

[pmid20166767-3] AG Malykh, MR Sadaie: Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders . In: Drugs . tape 70 , no. 3 , February 2010, p. 287-312 , doi : 10.2165 / 11319230-000000000-00000 , PMID 20166767 .

[4] Donald E. Butler, Ivan C. Nordin, Yvon J. L'Italien, Lynette Zweisler, Paul H. Poschel, John G. Marriott: Amnesia-reversal activity of a series of N - [(disubstituted-amino) alkyl] - 2-oxo-1-pyrrolidine acetamides, including pramiracetam . In: Journal of Medicinal Chemistry . tape 27 , no. 5 , 1984, pp. 684-691 , doi : 10.1021 / jm00371a023 .

[A._Kleemann-5] Axel Kleemann , Jürgen Engel, Bernd Kutscher, Dietmar Reichert: Pharmaceutical Substances. 4th edition. 2000, 2 volumes published by Thieme-Verlag Stuttgart, ISBN 978-1-58890-031-9 ; online since 2003 with biannual additions and updates.